Anzeige
Mehr »
Samstag, 27.12.2025 - Börsentäglich über 12.000 News
DiagnosTear: Massentaugliche Diagnose Technologien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLB7 | ISIN: CA88337V1004 | Ticker-Symbol: TTX
Frankfurt
23.12.25 | 08:01
0,083 Euro
-1,78 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERALASE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERALASE TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0860,10923.12.

Aktuelle News zur THERALASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiTheralase Technologies Inc: Theralase Technologies closes $1.33-million financing1
DiTheralase(R) closes $1.3M non-brokered private placement2
DiTheralase raises C$1.33 million in private placement for cancer study2
DiTheralase Technologies Inc.: Theralase(R) Closes $1.3 M Non-Brokered Private Placement205Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering...
► Artikel lesen
12.12.Theralase Technologies Inc: Theralase cancels $4.5M placement, arranges placement1
THERALASE Aktie jetzt für 0€ handeln
12.12.Theralase commences C$ 2M non-brokered private placement2
12.12.Theralase announces $2 million private placement offering1
12.12.Theralase Technologies Inc.: Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing356Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering light...
► Artikel lesen
24.11.Theralase Technologies Inc.: Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study162Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering light...
► Artikel lesen
17.11.Theralase Technologies Inc: Theralase to host conference call Nov. 192
17.11.Theralase Technologies Inc.: Theralase(R) Investor Conference Call Reminder181Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation...
► Artikel lesen
11.11.Theralase Technologies Inc: Theralase Technologies loses $3.43-million in Q34
10.11.Theralase Technologies Inc.: Theralase(R) Releases 3Q2025 Financial Statements327Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation...
► Artikel lesen
06.11.Buzz on the Bullboards: Baytex, Theralase, and Bombardier drive investor buzz this week7
03.11.Theralase Technologies Inc: Theralase says X-ray drug effective in cancer models3
03.11.Theralase Technologies Inc.: Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug937Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light...
► Artikel lesen
24.09.Theralase Technologies Inc: Theralase's ruvidar shown effective for herpes simplex2
24.09.Theralase Technologies Inc.: Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus276Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering...
► Artikel lesen
02.09.Theralase Technologies Inc: Theralase Technologies 1.84 million warrants extended2
02.09.Theralase Technologies is very undervalued, this analyst says1
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1